<DOC>
	<DOCNO>NCT02852577</DOCNO>
	<brief_summary>The purpose study determine whether clonazepam paroxetine effective treatment panic disorder . Efficacy evaluate short-term , long-term post-treatment .</brief_summary>
	<brief_title>Long Term Treatment Panic Disorder With Clonazepam Paroxetine</brief_title>
	<detailed_description>The current study consist three step . The first step naturalistic , prospective , randomize , open clinical trial clonazepam paroxetine . Subjects receive either flexible dose clonazepam ( 0.5 - 2 mg/day ) paroxetine ( 10 - 40 mg/day ) , monotherapy eight week . In second step , respond monotherapy short-term study continue drug dose . Partial responder non-responders invite receive combined pharmacological treatment clonazepam paroxetine . Patients receive maximum tolerated dos clonazepam paroxetine . The dos flexible , range 0.5 2 mg/day clonazepam 10 40 mg/day paroxetine . All patient treat 34 month second step . Patients complete second step remission include third step . For period four month medication taper . These patient follow 6 year evaluation year . Those relapse treat naturalistic basis , drug psychotherapy . This study conduct accordance ethical principle establish Declaration Helsinki Brazilian National Ethics Committee ( Conselho Nacional de Ã‰tica em Pesquisa - CONEP ) guideline . The local Ethics Committee approve study protocol . Written inform consent obtain patient .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Agoraphobia</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Clonazepam</mesh_term>
	<criteria>Diagnosis panic disorder , without agoraphobia accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , text revision ( DSMIVTR ) criterion , determine structured clinical interview . At least two panic attack week precede inclusion study . Patients unable unwilling provide write informed consent . Did complete evaluation study initiation . Had comorbidities could affect clinical evaluation include drug abuse , neurological disorder , severe personality disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>panic disorder</keyword>
	<keyword>agoraphobia</keyword>
	<keyword>clonazepam</keyword>
	<keyword>paroxetine</keyword>
</DOC>